Transforming Medicine to Better Life.
Driving the future of diabetes care, Insu Therapeutics is at the forefront of revolutionizing insulin administration.
A groundbreaking non-invasive delivery technology, eliminating the discomfort of traditional injections and enhancing patient experiences worldwide.
Pioneering Buccal Insulin Delivery Technology
Insu is enabling the next-generation of diabetes care with our patent-pending novel buccal insulin technology. The Insu buccal insulin tablet has demonstrated successful results in animal trials and is able to be equally absorbed in comparison to traditional injections. Furthermore, the Insu tablet is shelf-stable, eliminating the need for refrigeration and reducing environmental impact with less plastic waste, resulting in a more sustainable supply chain and broader accessibility to insulin.
Company Overview
Insu Therapeutics is an innovative UBC research-spinoff company redefining diabetes treatment with patent-pending, novel non-invasive insulin delivery technology, targeting the daily challenges of over 9 million type 1 diabetics and the broader needs of over half a billion people with diabetes globally.
​
Leveraging safe and known FDA-approved drugs in a new dosage form, Insu Therapeutics is on an accelerated pathway to commercialization, with Phase I and II clinical trials slated for 2024 and 2025. As we expand to address the high demand for effective insulin treatments, Insu Therapeutics intends to initiate R&D on other peptide drugs and set up Canada's first insulin manufacturing facility in the future.
Global Media Attention
The buccal delivery technology has attracted the attention of the media worldwide. Major news outlets and publishers have covered our breakthrough innovations, with press extending across North America, Europe, Middle East & Asia, South America and Africa - including national Canadian media, such as CBC, CTV, CityNews, and worldwide, such as Aljazeera, IndiaTimes, MIT News, Technology Networks, and many more.
AS FEATURED ON
